## Pascal Hammel

## List of Publications by Citations

Source: https://exaly.com/author-pdf/4612425/pascal-hammel-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30 1,212 14 33 h-index g-index citations papers 3.86 1,555 7.1 33 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
30	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1844-53	27.4	538
29	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 989-95	8.7	121
28	State of the art and future directions of pancreatic ductal adenocarcinoma therapy. <i>Pharmacology &amp; Therapeutics</i> , <b>2015</b> , 155, 80-104	13.9	66
27	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 1257-1271	3.3	65
26	Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 537-49	19.4	52
25	Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. <i>Pancreas</i> , <b>2015</b> , 44, 1141-7	2.6	48
24	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 2053-2064	7.5	44
23	Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. <i>European Journal of Cancer</i> , <b>2020</b> , 124, 91-101	7·5	40
22	Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018.	7.5	37
21	Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. Oncotarget, <b>2018</b> , 9, 26453-26465	3.3	24
20	Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor. <i>Neuroendocrinology</i> , <b>2020</b> , 110, 83-91	5.6	24
19	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. <i>European Journal of Human Genetics</i> , <b>2018</b> , 26, 1732-1742	5.3	23
18	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 337-346	18.8	20
17	Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. <i>Neuroendocrinology</i> , <b>2019</b> , 108, 343-353	5.6	20
16	Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5208-5216	12.9	12
15	Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Cooplateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial. <i>Trials</i> , <b>2015</b> , 16, 454	2.8	12
14	PARP inhibition in treatment of pancreatic cancer. Expert Review of Anticancer Therapy, 2020, 20, 939-9	94 <u>5</u> .5	10

## LIST OF PUBLICATIONS

13	Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 697-702	8.7	9
12	Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 39-47.e5	3.8	9
11	Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.	4.8	8
10	A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. <i>BMC Cancer</i> , <b>2015</b> , 15, 653	4.8	8
9	Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 358-368	5.3	7
8	Role of endoscopic ultrasound in the screening and follow-up of high-risk individuals for familial pancreatic cancer. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 5082-5096	5.6	7
7	Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine Tumours. <i>Neuroendocrinology</i> , <b>2020</b> , 110, 404-412	5.6	7
6	Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , <b>2021</b> , 21, 1064-1064	3.8	1
5	Gastrointestinal bleeding in patients with pancreatic cancer: Causes and haemostatic treatments. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 1106-1114	5.3	O
4	Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2021</b> , 45, 101607	2.4	O
3	Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential diagnosis with primary mucinous ovarian carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211053412	5.4	
2	Cervical bone pain revealing a bone metastatic colon cancer: A case report. <i>Molecular and Clinical Oncology</i> , <b>2020</b> , 13, 2	1.6	
1	Radiation Therapy Deviations in Trial of Locally Advanced Prostate Cancer-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 1409-1410	27.4	